Put companies on watchlist
MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News (52 News)
Country: Germany · Primary market: Germany · EQS NID: 1958211
31 July 2024 01:31PM

MEDICLIN reports solid first half of 2024


EQS-News: MEDICLIN AG / Key word(s): Half Year Results/Half Year Report
MEDICLIN reports solid first half of 2024

31.07.2024 / 13:31 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 31 July 2024
MEDICLIN reports solid first half of 2024
  • Consolidated sales up 0.9% to EUR 368.0 million in the first half of 2024
  • Group EBIT of EUR 11.9 million slightly higher than in the same period of the previous year (6M 2023: EUR 11.3 million)
  • Capacity utilisation rate up year-on-year at 85.2% (6M 2023: 83.6%)
  • Hospital reform expected at the turn of the year
Offenburg, 31 July 2024: In the first half of 2024, MEDICLIN Aktiengesellschaft (MEDICLIN) generated consolidated sales of EUR 368.0 million. This is EUR 3.2 million or 0.9 % more than in the first half of 2023. The consolidated operating result improved by EUR 0.6 million from EUR 11.3 million to EUR 11.9 million compared to the same period of the previous year. Overall capacity utilisation of 85.2% (6M 2023: 83.6%) underlines a solid first half-year.

Dr Joachim Ramming, CEO of MEDICLIN, comments: "We are in a challenging and dynamic environment. The hospital reform is drawing ever closer and is expected to come into force at the turn of the year. We are working intensely on our pioneering ambulatory and digitalisation projects to prepare ourselves for the expected changes in the healthcare market. We will make use of the opportunities arising from the changes."

"We look back on a solid first half of 2024. Our operating performance is particularly visible when we look at our consolidated sales and consolidated operating result without the distortion caused by protective shield benefits and divestments. Adjusted sales growth amounts to 6.8% or EUR 22.8 million. The absence of protective shield benefits in the first half of 2024 contributed EUR 4.7 million to the group operating result in the first half of the previous year.", reports Tino Fritz, CFO of MEDICLIN.

Sales and earnings performance of the segments

In the post-acute segment, sales increased by 4.9% to EUR 233.3 million
(6M 2023: EUR 222.3 million). The segment operating profit decreased by EUR 0.5 million to EUR 17.5 million (6M 2023: EUR 18.0 million). The cost of materials ratio rose by one percentage point to 21.1% (6M 2023: 20.1%). At EUR 49.3 million, the absolute cost of materials was 10.5% higher than in the previous year (6M 2023: EUR 44.6 million). Personnel expenses increased by EUR 4.2 million or 3.4% to EUR 125.6 million compared to the first half of the previous year. The personnel expenses ratio fell to 53.8% (6M 2023: 54.6%).

The acute segment reported a decline in segment sales of EUR 10.3 million or 7.9%. The segment operating profit amounted to EUR -3.9 million after EUR -5.3 million in the first half of 2023. The cost of materials fell by 9.7% to EUR 34.7 million (6M 2023: EUR 38.5 million). The cost of materials ratio declined slightly to 28.9%

(6M 2023: 29.5%). Personnel expenses totalled EUR 74.0 million and were therefore 7.0% lower than in the first six months of 2023 (6M 2023: EUR 79.6 million). The personnel expenses ratio was 61.5% after 60.9% in the same period of the previous year.

Sales in the Other Activities and Reconciliation segment totalled EUR 14.4 million, up EUR 2.5 million or 21.0% on the previous year. The nursing care business contributed sales of EUR 11.7 million to this figure, which corresponds to an increase of 14.7% compared to the previous year (6M 2023: EUR 10.2 million). At EUR -1.6 million, the segment operating profit was below the previous year's result of EUR -1.0 million.

Outlook and news

For the current financial year, the Management Board continues to expect a decline in sales of 0.0% to 2.0%. The Group operating result is now expected to be between EUR 33.0 million and EUR 39.0 million.

The interim report as at 30 June 2024 is available from today at www.mediclin.de in German and English.

For further information:
MEDICLIN Aktiengesellschaft
Okenstrasse 27
77652 Offenburg

Investor Relations
Ender Gülcan
Phone: 0781/488-326
ender.guelcan@mediclin.de


Public Relations
Dr Janina Lossen
Phone: 0781/488-180
janina.lossen@mediclin.de

www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 32 clinics, six care facilities and ten medical care centers. The Group has around 8,300 beds/care places and employs around 10,000 people. In a strong network, MEDICLIN offers the patient integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group
 


31.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1958211

 
End of News EQS News Service

1958211  31.07.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1958211&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - MEDICLIN AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.